Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC By Ogkologos - October 29, 2025 230 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the cohorts 1 and 2 of the TUXEDO-3 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Data from a Large Cohort of Patients with mRCC Demonstrate the... September 21, 2020 Dr. Alan S. Rabson, Long-Time NCI Deputy Director and Cancer Research... July 5, 2018 Disparities in Cancer Care Between Citizens and Refugees in Lebanon March 23, 2021 Researchers Believe Antibodies from Alpacas Could Be Key to Curing Cancer,... August 15, 2019 Load more HOT NEWS Higher Risk of Invasive Behaviour for Oncogenic Fusions–Driven Paediatric Thyroid Cancers Cetuximab Outperforms Durvalumab for Head and Neck Cancer When Cisplatin Isn’t... Modest Effectiveness of Screening Colonoscopy for the Prevention of Colorectal Cancer... Double Mastectomies Do Not Lower Risk Of Death For Breast Cancer...
